GRITSTONE BIO INC (GRTS) Stock Price, Forecast & Analysis
USA - NASDAQ:GRTS - US39868T1051 - Common Stock
GRTS Key Statistics, Chart & Performance
The current stock price of GRTS is 0.0322 USD. In the past month the price decreased by -94.46%. In the past year, price decreased by -98.3%.
GRTS Latest News, Press Relases and Analysis
GRTS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.85 | 381.38B | ||
| AMGN | AMGEN INC | 13.57 | 159.73B | ||
| GILD | GILEAD SCIENCES INC | 15.02 | 152.62B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.29 | 108.11B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.95 | 66.56B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 830.33 | 55.51B | ||
| ARGX | ARGENX SE - ADR | 62 | 51.19B | ||
| INSM | INSMED INC | N/A | 38.63B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5 | 33.96B | ||
| NTRA | NATERA INC | N/A | 26.96B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.20B | ||
| BIIB | BIOGEN INC | 8.92 | 21.89B |
Related stock screener links
About GRTS
Company Profile
Gritstone bio, Inc. clinical-stage biotechnology company, which engages in developing the next generation of cancer immunotherapies to fight multiple cancer types. The company is headquartered in Emeryville, California and currently employs 231 full-time employees. The company went IPO on 2018-09-28. The firm discovers, develops, manufactures and delivers next generation cancer and infectious disease immunotherapy candidates. The company has developed two vectors that it deploys with the aim of eliciting the desired immune response: self-amplifying mRNA (samRNA) and chimpanzee adenovirus (ChAd). Its two oncology programs in clinical-stage development are GRANITE, individualized neoantigen-based immunotherapy, and SLATE, an off-the-shelf shared neoantigen-based immunotherapy. The company has an infectious disease pipeline, which includes two programs in clinical-stage development: CORAL, a second-generation COVID-19 vaccine program that may have pan-coronavirus potential to protect against future coronavirus pandemics, and an HIV therapeutic/cure vaccine candidate. In oncology, it develops personalized vaccines that aim to destroy tumors through CD8+ (killer) T cell recognition of tumor cells by virtue of their surface display of neoantigens.
Company Info
GRITSTONE BIO INC
5959 Horton Street, Suite 300
Emeryville CALIFORNIA 94608 US
CEO: Andrew Allen
Employees: 231
Phone: 15108716100
GRITSTONE BIO INC / GRTS FAQ
What does GRITSTONE BIO INC do?
Gritstone bio, Inc. clinical-stage biotechnology company, which engages in developing the next generation of cancer immunotherapies to fight multiple cancer types. The company is headquartered in Emeryville, California and currently employs 231 full-time employees. The company went IPO on 2018-09-28. The firm discovers, develops, manufactures and delivers next generation cancer and infectious disease immunotherapy candidates. The company has developed two vectors that it deploys with the aim of eliciting the desired immune response: self-amplifying mRNA (samRNA) and chimpanzee adenovirus (ChAd). Its two oncology programs in clinical-stage development are GRANITE, individualized neoantigen-based immunotherapy, and SLATE, an off-the-shelf shared neoantigen-based immunotherapy. The company has an infectious disease pipeline, which includes two programs in clinical-stage development: CORAL, a second-generation COVID-19 vaccine program that may have pan-coronavirus potential to protect against future coronavirus pandemics, and an HIV therapeutic/cure vaccine candidate. In oncology, it develops personalized vaccines that aim to destroy tumors through CD8+ (killer) T cell recognition of tumor cells by virtue of their surface display of neoantigens.
What is the current price of GRTS stock?
The current stock price of GRTS is 0.0322 USD. The price decreased by -31.78% in the last trading session.
Does GRTS stock pay dividends?
GRTS does not pay a dividend.
What is the ChartMill technical and fundamental rating of GRTS stock?
GRTS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the growth outlook for GRITSTONE BIO INC?
The Revenue of GRITSTONE BIO INC (GRTS) is expected to decline by -74.34% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the employee count for GRTS stock?
GRITSTONE BIO INC (GRTS) currently has 231 employees.
GRTS Technical Analysis
GRTS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GRTS. GRTS has a bad profitability rating. Also its financial health evaluation is rather negative.
GRTS Financial Highlights
Over the last trailing twelve months GRTS reported a non-GAAP Earnings per Share(EPS) of -1.09. The EPS increased by 13.49% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -93.33% | ||
| ROE | -599.53% | ||
| Debt/Equity | 1.83 |
GRTS Forecast & Estimates
6 analysts have analysed GRTS and the average price target is 0.77 USD. This implies a price increase of 2275.78% is expected in the next year compared to the current price of 0.0322.
For the next year, analysts expect an EPS growth of 19.29% and a revenue growth -74.34% for GRTS